<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154838">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070991</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055G201</org_study_id>
    <nct_id>NCT02070991</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension Due to Left Ventricular Dysfunction</brief_title>
  <acronym>MELODY-1</acronym>
  <official_title>A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of
      subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left
      ventricular dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of macitentan 10 mg in subjects with CpcPH</measure>
    <time_frame>Baseline to End of Study (30 days after last dose)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of subjects experiencing one of the following up to EOT:
Significant fluid retention, defined as one of the following:
Increase in body weight at any time by ≥ 5% or ≥ 5 kg from baseline due to fluid overload.
Parenteral administration of diuretics.
Worsening in NYHA functional class from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of macitentan 10 mg in subjects with CpcPH</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>PVR at rest at Week 12 expressed as percent of baseline PVR at rest. Change from baseline to Week 12 in mean right atrial pressure, mPAP, cardiac index, cardiac output, total pulmonary resistance, transpulmonary gradient (TPG [mPAP − PAWP]), DPG and mixed venous oxygen saturation at rest. Change from baseline to Week 12 in echocardiographic parameters of diastolic and systolic function (i.e., LVEF, tricuspid annular plane systolic excursion, tricuspid regurgitation velocity, diastolic wall thickness of the septum and the left ventricular free wall, E/e' ratio, left atrial volume).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pre-capillary Pulmonary Hypertension</condition>
  <condition>Post-capillary Pulmonary Hypertension</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, 10 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan</intervention_name>
    <description>oral tablet, 10 mg once daily</description>
    <arm_group_label>Macitentan</arm_group_label>
    <other_name>Macitentan</other_name>
    <other_name>ACT-064992</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and Females &gt;=18 years of age

          2. Subjects with combined pre-and post-capillary Pulmonary Hypertension (CpcPH) due to
             left ventricular dysfunction (subset of WHO groups 2.1 and 2.2)

          3. Optimized diuretic therapy

        Exclusion Criteria:

          1. Types of Pulmonary Hypertension other than WHO groups 2.1 and 2.2 (Nice
             classification)

          2. Administration of PAH-specific therapy (i.e., Endothelin receptor antagonists (ERAs),
             Prostanoids, Phosphodiesterase 5 (PDE-5) inhibitors, guanylate cyclase stimulators)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Roux, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LIU Center for Pulmonary Hypertension</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Oudiz</last_name>
      <phone>310-222-2515</phone>
      <email>roudiz@labiomed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John W. McConnell</last_name>
      <phone>502-587-8000</phone>
      <email>mcco3526@bellsouth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harrison W Farber</last_name>
      <phone>617-638-4860</phone>
      <email>hfarber@bu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Internal Medicine Cardiology, Pulmonary Hypertension Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vallerie McLaughlin</last_name>
      <phone>734-936-5383</phone>
      <email>vmclaugh@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center, Pulmonary Unit</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yochai Adir</last_name>
      <phone>972-4-8250517</phone>
      <email>yochaiad@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Pulmonology Hadassah Medical Centre : Ein Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neville Berkman</last_name>
      <phone>+972 2 677 77 83</phone>
      <email>neville@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Centre / Pulmonary Institute and Department of Medicine</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Starobin</last_name>
      <phone>+972 8 9441211</phone>
      <email>daniel_s@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center / The Institute of Pulmonology, Physiology and Exercise</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Segel</last_name>
      <phone>+972-3-530-3030</phone>
      <email>Michael.Segel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S. Orsola-Malpighi - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Unità Operativa di Cardiologia</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nazzareno Galiè</last_name>
      <phone>+39 051 6363434</phone>
      <email>nazzareno.galie@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Servicio de Cardiologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Félix Pérez Villa</last_name>
      <phone>+34 932275400 ext. 2035</phone>
      <email>fperez@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron Servicio de Cardiologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enric Domingo Ribas</last_name>
      <phone>+34 93 489 30 00</phone>
      <email>edrcg@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia Servicio de Cardiologia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José María Arizón del Prado</last_name>
      <phone>+34 957 010 504</phone>
      <email>josem.arizon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre Servicio de Cardiología</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Angel Gomez Sanchez</last_name>
      <phone>(+) 34 91390 8289</phone>
      <email>mangomezs@telefonica.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left heart failure LLT</keyword>
  <keyword>Pulmonary Hypertension LLT</keyword>
  <keyword>CpcPH</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
